Participated · Series A · Aug 2026

Velaura AI develops energy-efficient digital design technology for AI compute, built on patented techniques applied at leading semiconductor process nodes. Its flagship product, Titan Core, is a proprietary chip IP and design platform that the company says delivers a 2x to 4x improvement in performance per watt on the mathematical operations used by AI accelerators without sacrificing performance. The underlying technology has been deployed across more than 30 million ASICs, and Velaura licenses it under an upfront fee plus a royalty tied to the power savings its customers achieve. The company says it is engaged with hyperscalers and chip partners at 3nm and 2nm nodes to integrate the technology into next-generation AI accelerators, and is extending the architecture into physical AI systems including robots, drones, and autonomous machines. Founded in 2022 as Auradine, a bitcoin mining ASIC designer behind the Teraflux miner series, the company rebranded to Velaura AI in March 2026 alongside a pivot to AI silicon, and is headquartered at 3200 Coronado Drive in Santa Clara, California. Financially, Velaura AI announced a $110M Series A in August 2026 at a valuation above $1 billion, led by Seligman Ventures; the articles do not state a cumulative total raised across its earlier rounds under the Auradine name.

Participated · Series B · Aug 2026

Founded in 2018 and cultivated in Xishan, Jiangsu Eyou Robot Technology focuses on the research and production of integrated servo joint modules that combine motors, reducers, drivers, and encoders. Its integrated joints emphasize compact structure, control precision, and operational stability, and the company serves over 500 domestic and overseas enterprises including AGIBOT, TARS, iFLYTEK, FAW, TCL, Midea, Siemens, and Haier. The business spans Japan, South Korea, North America, and Southeast Asia, with overseas markets showing sustained growth. Orders in hand for joints have surpassed 1.5 million sets in 2026, a 15-fold increase over its total shipments for 2025. To meet demand, Eyou established what it calls the world's first fully automated production line for integrated joints in Shanghai Zhangjiang Robot Valley, producing a harmonic joint in 60 seconds with a 98% pass rate. The company has put 36,000 square meters of factory space into use at its Wuxi production base and acquired 34 mu of industrial land for a new smart manufacturing facility that will support a delivery capacity of 10 million units.

Participated · Series A · Aug 2026

Silicon Data provides pricing indices, performance benchmarks, forward curves and market intelligence for the AI compute economy, aimed at buyers, sellers, exchanges and financial institutions. It has built a portfolio of nine financial-grade indices covering GPUs and LLMs and offers alternative datasets that track supply, demand, utilization, pricing and economics across compute. The company has over 1,000 registered users and counts semiconductor manufacturers, AI model builders and financial institutions among its daily users. SiliconMark, a product funded by the Series A, benchmarks real-world GPU cluster performance to normalize output differences driven by networking, topology and configuration. Silicon Data spent two years building the pricing and performance history needed to support a futures market and is positioned to be the reference layer for cash-settled GPU futures being planned by CME Group. Financially, the company raised a $4.7 million seed in March 2025 and completed a $30.5 million Series A initial closing to fund its next phase of product and market expansion.

Participated · Series D · Jul 2026

FORE Biotherapeutics is a registration-stage targeted oncology company whose lead asset is plixorafenib (FORE8394; formerly PLX8394), a BRAF inhibitor with a mechanism described as both a dimer and paradox breaker. The company is advancing plixorafenib in the global Phase 2 FORTE Master Protocol, a registration-intended basket study that includes monotherapy baskets for recurrent or progressive BRAF V600E primary CNS tumors, rare BRAF V600 mutated solid tumors, and advanced solid tumors with BRAF fusions. Fore reported that target enrollment of approximately 50 patients has been reached in the BRAF V600E CNS tumor basket and expects topline results from that basket around the end of 2026; the company anticipates a potential regulatory submission if the primary analysis is positive. Plixorafenib received Breakthrough Therapy Designation from the FDA in April 2026, and prior Phase 1/2 data showed a 67% ORR in MAPK inhibitor–naïve BRAF V600 primary recurrent CNS tumors (n=9) and a 42% response rate with a median duration of response of 17.8 months in V600-altered, MAPK inhibitor–naïve patients. The company reported a favorable safety profile for plixorafenib, including a drug-related discontinuation rate of less than 2%, and has implemented protocol changes in FORTE such as allowing dosing with food and lowering the minimum enrollment age to 8 years based on IDMC clearance.

Led · Series A · Jul 2026

OXMIQ develops a licensable GPU core, OxCore™, that integrates a CUDA-compatible GPU engine, a tensor processing engine, and an orchestration engine to enable configurable AI silicon. Its OxQuilt™ chiplet integration architecture supports heterogeneous compute and memory configurations across foundries and packaging options, and OxPython™ and OxCapsule™ provide software portability and orchestration for running existing CUDA and PyTorch code. OxCore is running on FPGA today with live demonstrations available, and the company positions an IP-first model to generate revenue from customer engagements while conserving capital. OXMIQ is working with semiconductor companies, neoclouds, AI system builders, and partners such as MediaTek and AM Intelligence Labs on initiatives including a renewable-powered AI factory collaboration. The company has strengthened its governance with additions to its board and advisory ranks to support customer integration and scaling. Financially, OXMIQ has raised $60 million in total capital following the $35 million Series A.